| abstract |
The present disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group that target prostate specific membrane antigen (PSMA), such as prostate specific membrane antigen in prostate cancer. The compound has formula I, wherein each R1 is an anionic group, L is a linker, and R2B-F3 is -N(R 3 ) 2 CH 2 BF 3 , pyridinium substituted by BF 3 or methyl BF 3 group, or an azole group substituted by methyl BF3. Also disclosed are methods and uses of imaging and treating PSMA-expressing cancers. |